CSTL (Castle Biosciences) Marketable Securities: $204.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSTL Castle Biosciences Inc CSTL
82 GF Score
Price $33.49
GF Value $29.70
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Marketable Securities?

Castle Biosciences CSTL -2.28% 82 Marketable Securities is $204.7 Mil as of Jun. 2026. GuruFocus rates CSTL with a GF Score™ of 82/100 and a GF Value™ of $29.70 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Castle Biosciences's Marketable Securities for the quarter that ended in Jun. 2026 was $204.7 Mil.

Castle Biosciences's annual Marketable Securities increased from Dec. 2023 ($144.3 Mil) to Dec. 2024 ($173.4 Mil) and increased from Dec. 2024 ($173.4 Mil) to Dec. 2025 ($182.8 Mil).

Castle Biosciences  (NAS:CSTL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Castle Biosciences Marketable Securities Related Terms

Castle Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Marketable Securities Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 0.00 135.68 144.26 173.42 182.78

Castle Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 193.70 201.99 182.78 197.92 204.69
CSTL
82GF Score
Castle Biosciences Inc CSTL
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $204.7 Mil mean?
Castle Biosciences (CSTL) has a Marketable Securities of $204.7 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Marketable Securities too high?
Castle Biosciences' current Marketable Securities is $204.7 Mil. Overall, Castle Biosciences has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Marketable Securities compare to OPK and FLGT?
Castle Biosciences' Marketable Securities of $204.7 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Marketable Securities is $204.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.70, compared to a current price of $33.49 — trading 12.8% above its estimated fair value. The current Marketable Securities is $204.7 Mil. Castle Biosciences' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Marketable Securities is $204.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued. The current stock price of $33.49 is trading 12.8% above its estimated GF Value™ of $29.70. GuruFocus considers Castle Biosciences to be Modestly Overvalued.

Key valuation signals for CSTL:

  • Marketable Securities: $204.7 Mil
  • GF Value™: $29.70 vs. price of $33.49 (12.8% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
82GF Score

Get the complete analysis for CSTL

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.49
Price
$29.70
GF Value